PPARα agonists are used in the treatment of dyslipidemia and are being examined for their ability to ameliorate NAFLD, illustrating the importance of PPARα in lipid metabolism [19]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.